You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAripiprazole
Accession NumberDB01238  (APRD00638)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Structure
Thumb
Synonyms
Abilify
Abilitat
Aripiprazol
Aripiprazole
Aripiprazolum
OPC 31
External Identifiers
  • OPC-14597
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet15 mg/1oralCarilion Materials Management2002-11-152016-04-05Us
Abilifytablet10 mg/1oralbryant ranch prepack2002-11-152016-04-05Us
Abilifytablet5 mg/1oralCarilion Materials Management2002-11-152016-04-05Us
Abilifytablet5 mg/1oralH.J. Harkins Company, Inc.2002-11-152016-04-05Us
Abilifytablet2 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-052016-04-05Us
Abilifytablet2 mg/1oralSTAT Rx USA LLC2002-11-152016-04-05Us
Abilifyinjection, solution9.75 mg/1.3mLintramuscularOtsuka America Pharmaceutical, Inc.2006-09-202016-04-05Us
Abilifytablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-11-152016-04-05Us
Abilifytablet10 mg/1oralPhysicians Total Care, Inc.2006-01-312016-04-05Us
Abilifytablet5 mg/1oralbryant ranch prepack2002-11-152016-04-05Us
Abilifytablet30.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet20 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-282016-04-05Us
Abilifytablet30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-172016-04-05Us
Abilifysolution1 mg/mLoralOtsuka America Pharmaceutical, Inc.2004-12-102016-04-05Us
Abilifytablet30 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet2 mg/1oralbryant ranch prepack2002-11-152016-04-05Us
Abilifytablet20.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-06-032016-04-05Us
Abilifytablet5 mg/1oralREMEDYREPACK INC.2013-05-102016-03-31Us
Abilifytablet30 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet15 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet, orally disintegrating15 mg/1oralOtsuka America Pharmaceutical, Inc.2006-06-072016-04-05Us
Abilifytablet15.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-172016-04-05Us
Abilifytablet20 mg/1oralRebel Distributors Corp.2002-11-152016-04-05Us
Abilifytablet20 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet20 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet10 mg/1oralTYA Pharmaceuticals2002-11-152016-04-05Us
Abilifytablet, orally disintegrating10 mg/1oralOtsuka America Pharmaceutical, Inc.2006-06-072016-04-05Us
Abilifytablet10.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-172016-04-05Us
Abilifytablet15 mg/1oralRebel Distributors Corp.2002-11-152016-04-05Us
Abilifytablet15 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet5 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet30 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-152016-04-05Us
Abilifytablet10 mg/1oralRebel Distributors Corp.2002-11-152016-04-05Us
Abilifytablet10 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet2 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet15 mg/1oralTYA Pharmaceuticals2002-11-152016-04-05Us
Abilifytablet5.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet5 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet10 mg/1oralCardinal Health2002-11-152016-04-05Us
Abilifytablet5 mg/1oralTYA Pharmaceuticals2002-11-152016-04-05Us
Abilifytablet2.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-152016-04-05Us
Abilifytablet5 mg/1oralRebel Distributors Corp.2002-11-152016-04-05Us
Abilifytablet2 mg/1oralTYA Pharmaceuticals2002-11-152016-04-05Us
Abilifytablet2 mg/1oralCarilion Materials Management2002-11-152016-04-05Us
Abilifytablet10 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-152016-04-05Us
Abilifytablet5 mg/1oralSTAT Rx USA LLC2002-11-152016-04-05Us
Abilifytablet2 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-152016-04-05Us
Abilifytablet2 mg/1oralPhysicians Total Care, Inc.2011-07-182016-04-05Us
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-282016-04-05Us
Abilify Maintenapowder for suspension, sustained-release; kit300 mgintramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-082016-04-05Us
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-082016-04-05Us
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-282016-04-05Us
Abilify Maintenapowder for suspension, sustained-release; kit400 mgintramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Aristadainjection, suspension, extended release882 mg/3.2mLintramuscularAlkermes, Inc.2015-10-052016-04-05Us
Aristadainjection, suspension, extended release662 mg/2.4mLintramuscularAlkermes, Inc.2015-10-052016-04-05Us
Aristadainjection, suspension, extended release441 mg/1.6mLintramuscularAlkermes, Inc.2015-10-052016-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet15 mg/1oralREMEDYREPACK INC.2010-12-142015-12-29Us
Aripiprazoletablet20 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet10 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet5 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet10 mg/1oralREMEDYREPACK INC.2015-12-082016-04-05Us
Aripiprazoletablet5 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazolesolution1 mg/mLoralApotex Corp.2015-10-082016-04-05Us
Aripiprazoletablet2 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet20 mg/1oralREMEDYREPACK INC.2015-12-242016-04-05Us
Aripiprazoletablet5 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazoletablet, orally disintegrating15 mg/1oralTrigen Laboratories, LLC2015-05-212016-04-05Us
Aripiprazoletablet30 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet30 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet20 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet10 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazoletablet5 mg/1oralREMEDYREPACK INC.2015-10-192016-04-05Us
Aripiprazoletablet2 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazoletablet, orally disintegrating15 mg/1oralAlembic Pharmaceuticals Limited2015-05-212016-04-05Us
Aripiprazoletablet30 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet2 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazoletablet, orally disintegrating10 mg/1oralTrigen Laboratories, LLC2015-05-212016-04-05Us
Aripiprazoletablet20 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet15 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet15 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet5 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet10 mg/1oralREMEDYREPACK INC.2015-06-162016-04-05Us
Aripiprazoletablet2 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet, orally disintegrating10 mg/1oralAlembic Pharmaceuticals Limited2015-05-212016-04-05Us
Aripiprazoletablet20 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet30 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet30 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet15 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet10 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet10 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet2 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet5 mg/1oralREMEDYREPACK INC.2015-05-192016-04-05Us
Aripiprazoletablet30 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet30 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet15 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet20 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet20 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet10 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet5 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet5 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet2 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet30 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazoletablet20 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet20 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet10 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet15 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet15 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet5 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet2 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet2 mg/1oralTorrent Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet30 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet10 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet10 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet2 mg/1oralGolden State Medical Supply, Inc.2015-07-282016-04-05Us
Aripiprazoletablet30 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazoletablet30 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet20 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet20 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazoletablet15 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet15 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet5 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet5 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet20 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazoletablet20 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet15 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet15 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazoletablet10 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet10 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazoletablet2 mg/1oralAurobindo Pharma Limited2015-10-082016-04-05Us
Aripiprazoletablet5 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet15 mg/1oralMajor Pharmaceuticals2015-08-252016-04-05Us
Aripiprazoletablet10 mg/1oralTeva Pharmaceuticals USA Inc2015-04-282016-04-23Us
Aripiprazoletablet10 mg/1oralAmerican Health Packaging2015-06-052016-04-05Us
Aripiprazoletablet5 mg/1oralApotex Corp2015-07-242016-04-05Us
Aripiprazoletablet5 mg/1oralAlembic Pharmaceuticals Limited2015-04-282016-04-05Us
Aripiprazolesolution1 mg/mLoralAmneal Pharmaceuticals of New York, LLC2015-08-172016-04-05Us
Aripiprazoletablet2 mg/1oralCamber Pharmaceuticals, Inc.2015-05-052016-04-05Us
Aripiprazoletablet2 mg/1oralTrigen Laboratories, LLC2015-04-282016-04-05Us
Aripiprazoletablet30 mg/1oralSafecor Health, LLC2015-12-012016-04-05Us
Aripiprazoletablet15 mg/1oralAv Kare, Inc.2015-08-062016-04-05Us
Aripiprazole Oral Solutionsolution1 mg/mLoralSilarx Pharmaceuticals, Inc2015-08-172016-04-05Us
Over the Counter ProductsNot Available
International Brands
NameCompany
AbilitatNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Aripiprazole lauroxil
ThumbNot applicableDBSALT001351
Categories
UNII82VFR53I78
CAS number129722-12-9
WeightAverage: 448.385
Monoisotopic: 447.148032537
Chemical FormulaC23H27Cl2N3O2
InChI KeyInChIKey=CEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Quinolone
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Substituted aniline
  • Dialkylarylamine
  • 1,2-dichlorobenzene
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsAripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionAripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 4.9 L/kg
Protein binding>99%
Metabolism

Hepatic.

Route of eliminationLess than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
Half life75-146 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 inhibitorInhibitor0.6682
CYP450 2D6 inhibitorInhibitor0.6633
CYP450 2C19 inhibitorInhibitor0.8934
CYP450 3A4 inhibitorInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular9.75 mg/1.3mL
Tabletoral10.0 mg
Tabletoral15.0 mg
Tabletoral2.0 mg
Tabletoral20.0 mg
Tabletoral30.0 mg
Tabletoral5.0 mg
Kit
Powder for suspension, sustained-release; kitintramuscular300 mg
Powder for suspension, sustained-release; kitintramuscular400 mg
Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral2 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral5 mg/1
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
Solutionoral1 mg/mL
Injection, suspension, extended releaseintramuscular441 mg/1.6mL
Injection, suspension, extended releaseintramuscular662 mg/2.4mL
Injection, suspension, extended releaseintramuscular882 mg/3.2mL
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006528 No1994-10-202014-10-20Us
US6977257 Yes2002-10-242022-10-24Us
US7053092 No2002-01-282022-01-28Us
US7115587 Yes2005-01-212025-01-21Us
US7550445 Yes2005-01-212025-01-21Us
US7807680 No2004-10-192024-10-19Us
US8017615 Yes2004-12-162024-12-16Us
US8030313 No2004-10-192024-10-19Us
US8338427 No2005-03-152025-03-15Us
US8338428 No2003-08-062023-08-06Us
US8399469 No2005-06-292025-06-29Us
US8431576 No2010-10-262030-10-26Us
US8518421 Yes2001-07-242021-07-24Us
US8580796 Yes2003-03-252023-03-25Us
US8642600 Yes2002-07-282022-07-28Us
US8642760 Yes2003-03-252023-03-25Us
US8722679 No2004-10-192024-10-19Us
US8759350 No2007-03-022027-03-02Us
US8759351 No2003-08-062023-08-06Us
US8796276 No2010-06-242030-06-24Us
US8993761 No2002-09-252022-09-25Us
US9034867 No2012-11-072032-11-07Us
US9089567 No2002-01-282022-01-28Us
US9125939 No2006-07-282026-07-28Us
US9193685 No2013-10-242033-10-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceUS5006528
General ReferencesNot Available
External Links
ATC CodesN05AX12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (262 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Aripiprazole can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Aripiprazole can be increased when it is combined with Acebutolol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.
AlprazolamThe serum concentration of Aripiprazole can be increased when it is combined with Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.
AmitriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Aripiprazole can be increased when it is combined with Amlodipine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Aripiprazole.
AmphetamineAripiprazole may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Aprepitant.
ArmodafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil.
AtazanavirThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.
AtomoxetineThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Atorvastatin.
AzelastineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Aripiprazole.
BenzphetamineAripiprazole may decrease the stimulatory activities of Benzphetamine.
BetaxololThe serum concentration of Aripiprazole can be increased when it is combined with Betaxolol.
BexaroteneThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Aripiprazole can be increased when it is combined with Bicalutamide.
BoceprevirThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Aripiprazole.
BuprenorphineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.
CalcitriolThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.
CarbamazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.
CathinoneAripiprazole may decrease the stimulatory activities of Cathinone.
CelecoxibThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.
CeritinibThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.
ChlorphenamineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.
CholecalciferolThe serum concentration of Aripiprazole can be increased when it is combined with Cholecalciferol.
CilostazolThe serum concentration of Aripiprazole can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.
CiprofloxacinThe serum concentration of Aripiprazole can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Aripiprazole.
ClarithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.
ClobazamThe serum concentration of Aripiprazole can be decreased when it is combined with Clobazam.
ClomipramineThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Aripiprazole can be increased when it is combined with Clozapine.
CobicistatThe serum concentration of Aripiprazole can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Aripiprazole can be increased when it is combined with Cocaine.
ConivaptanThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.
CyclosporineThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Aripiprazole can be increased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.
DanazolThe serum concentration of Aripiprazole can be increased when it is combined with Danazol.
DarifenacinThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.
DarunavirThe serum concentration of Aripiprazole can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.
DesipramineThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.
DexamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.
DextroamphetamineAripiprazole may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe serum concentration of Aripiprazole can be increased when it is combined with Dextromethorphan.
DicloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aripiprazole.
DiltiazemThe serum concentration of Aripiprazole can be increased when it is combined with Diltiazem.
DiphenhydramineThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.
DisulfiramThe serum concentration of Aripiprazole can be increased when it is combined with Disulfiram.
DofetilideAripiprazole may increase the QTc-prolonging activities of Dofetilide.
DolasetronThe serum concentration of Aripiprazole can be increased when it is combined with Dolasetron.
DonepezilDonepezil may increase the central neurotoxic activities of Aripiprazole.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Aripiprazole.
DoxorubicinThe serum concentration of Aripiprazole can be increased when it is combined with Doxorubicin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
DuloxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.
EfavirenzThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aripiprazole.
EnalaprilatAripiprazole may increase the hypotensive activities of Enalaprilat.
EntacaponeThe serum concentration of Aripiprazole can be increased when it is combined with Entacapone.
EnzalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.
ErythromycinThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Aripiprazole.
Eslicarbazepine acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol.
EthanolAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EtravirineThe serum concentration of Aripiprazole can be decreased when it is combined with Etravirine.
ExemestaneThe serum concentration of Aripiprazole can be decreased when it is combined with Exemestane.
FelbamateThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.
FelodipineThe serum concentration of Aripiprazole can be increased when it is combined with Felodipine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.
FexofenadineThe serum concentration of Aripiprazole can be increased when it is combined with Fexofenadine.
FlecainideThe serum concentration of Aripiprazole can be increased when it is combined with Flecainide.
FluconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.
FluphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.
FluvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Fluvastatin.
FluvoxamineThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Aripiprazole can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Aripiprazole can be decreased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.
Fusidic AcidThe serum concentration of Aripiprazole can be increased when it is combined with Fusidic Acid.
GalantamineGalantamine may increase the central neurotoxic activities of Aripiprazole.
GefitinibThe serum concentration of Aripiprazole can be increased when it is combined with Gefitinib.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.
Glycerol PhenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Glycerol Phenylbutyrate.
GoserelinAripiprazole may increase the QTc-prolonging activities of Goserelin.
GriseofulvinThe serum concentration of Aripiprazole can be decreased when it is combined with Griseofulvin.
HaloperidolAripiprazole may increase the QTc-prolonging activities of Haloperidol.
HydrocodoneAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydrocortisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.
HydroxyzineThe serum concentration of Aripiprazole can be increased when it is combined with Hydroxyzine.
IdelalisibThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Aripiprazole can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Aripiprazole.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Aripiprazole.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Aripiprazole.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.
IrbesartanThe serum concentration of Aripiprazole can be increased when it is combined with Irbesartan.
IsavuconazoniumThe serum concentration of Aripiprazole can be decreased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aripiprazole.
IsoniazidThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.
IsosorbideAripiprazole may increase the hypotensive activities of Isosorbide.
ItraconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Aripiprazole can be increased when it is combined with Lapatinib.
LeuprolideAripiprazole may increase the QTc-prolonging activities of Leuprolide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aripiprazole.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.
LisdexamfetamineAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Aripiprazole.
LomitapideThe serum concentration of Aripiprazole can be increased when it is combined with Lomitapide.
LomustineThe serum concentration of Aripiprazole can be increased when it is combined with Lomustine.
LoratadineThe serum concentration of Aripiprazole can be increased when it is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.
LorcaserinThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.
LuliconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
Medroxyprogesterone AcetateThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone Acetate.
MefloquineThe serum concentration of Aripiprazole can be increased when it is combined with Mefloquine.
MequitazineAripiprazole may increase the arrhythmogenic activities of Mequitazine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Aripiprazole.
MethamphetamineAripiprazole may decrease the stimulatory activities of Methamphetamine.
MethimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methimazole.
MethotrimeprazineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethoxsalenThe serum concentration of Aripiprazole can be increased when it is combined with Methoxsalen.
MethylphenidateThe serum concentration of Aripiprazole can be increased when it is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.
MetoprololThe serum concentration of Aripiprazole can be increased when it is combined with Metoprolol.
MetyraponeThe serum concentration of Aripiprazole can be decreased when it is combined with Metyrapone.
MetyrosineAripiprazole may increase the sedative activities of Metyrosine.
MifepristoneThe serum concentration of Aripiprazole can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Aripiprazole.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
MirabegronThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.
MirtazapineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.
MoclobemideThe serum concentration of Aripiprazole can be increased when it is combined with Moclobemide.
ModafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Modafinil.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
NafcillinThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aripiprazole.
NelfinavirThe serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Aripiprazole can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Aripiprazole can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Aripiprazole can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Aripiprazole can be increased when it is combined with Nifedipine.
NortriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.
OlanzapineThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.
OmeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Omeprazole.
OndansetronThe serum concentration of Aripiprazole can be increased when it is combined with Ondansetron.
OritavancinThe serum concentration of Aripiprazole can be decreased when it is combined with Oritavancin.
OrphenadrineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OspemifeneThe serum concentration of Aripiprazole can be increased when it is combined with Ospemifene.
OxcarbazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine.
OxybutyninThe serum concentration of Aripiprazole can be increased when it is combined with Oxybutynin.
PaclitaxelThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.
PantoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.
ParaldehydeAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.
PazopanibThe serum concentration of Aripiprazole can be increased when it is combined with Pazopanib.
Peginterferon alfa-2bThe serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe serum concentration of Aripiprazole can be increased when it is combined with Pentamidine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
PerphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.
PhendimetrazineAripiprazole may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aripiprazole.
PhenobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Phenobarbital.
PhentermineAripiprazole may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Phenytoin.
PindololThe serum concentration of Aripiprazole can be increased when it is combined with Pindolol.
PioglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.
PosaconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.
PraziquantelThe serum concentration of Aripiprazole can be increased when it is combined with Praziquantel.
PrednisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.
PrimaquineThe serum concentration of Aripiprazole can be increased when it is combined with Primaquine.
PrimidoneThe serum concentration of Aripiprazole can be decreased when it is combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.
PromazineThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.
PromethazineThe serum concentration of Aripiprazole can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.
PropofolThe serum concentration of Aripiprazole can be increased when it is combined with Propofol.
PropranololThe serum concentration of Aripiprazole can be increased when it is combined with Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aripiprazole.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.
QuinidineThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.
RabeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rabeprazole.
RanitidineThe serum concentration of Aripiprazole can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aripiprazole.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.
RifabutinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Aripiprazole can be decreased when it is combined with Rifapentine.
RisperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.
RitonavirThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Aripiprazole.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.
RolapitantThe serum concentration of Aripiprazole can be increased when it is combined with Rolapitant.
RufinamideThe serum concentration of Aripiprazole can be decreased when it is combined with Rufinamide.
SaquinavirThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.
SelegilineThe serum concentration of Aripiprazole can be increased when it is combined with Selegiline.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Aripiprazole.
SiltuximabThe serum concentration of Aripiprazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Aripiprazole can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Simvastatin.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Sodium phenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Sodium phenylbutyrate.
St. John's WortThe serum concentration of Aripiprazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Aripiprazole can be increased when it is combined with Stiripentol.
SulconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulconazole.
SulpirideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.
SuvorexantAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineTacrine may increase the central neurotoxic activities of Aripiprazole.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.
TelaprevirThe serum concentration of Aripiprazole can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Telithromycin.
TemsirolimusThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.
TerbinafineThe serum concentration of Aripiprazole can be decreased when it is combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.
ThalidomideAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe serum concentration of Aripiprazole can be increased when it is combined with Thioridazine.
ThiothixeneThe serum concentration of Aripiprazole can be increased when it is combined with Thiothixene.
TicagrelorThe serum concentration of Aripiprazole can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Aripiprazole can be increased when it is combined with Ticlopidine.
TimololThe serum concentration of Aripiprazole can be increased when it is combined with Timolol.
TioconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tioconazole.
TipranavirThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.
TopiramateThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.
TrametinibThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.
TranylcypromineThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Aripiprazole.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aripiprazole.
TriprolidineThe serum concentration of Aripiprazole can be increased when it is combined with Triprolidine.
VemurafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.
VilazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.
VinblastineThe serum concentration of Aripiprazole can be increased when it is combined with Vinblastine.
VinorelbineThe serum concentration of Aripiprazole can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Aripiprazole.
ZafirlukastThe serum concentration of Aripiprazole can be increased when it is combined with Zafirlukast.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.
ZolpidemAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. [PubMed:14642974 ]
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. [PubMed:17265076 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistpartial agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. [PubMed:16366516 ]
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. [PubMed:9083792 ]
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. [PubMed:16925992 ]
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. [PubMed:16981227 ]
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. [PubMed:17501690 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. [PubMed:12063084 ]
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. [PubMed:14647959 ]
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. [PubMed:14709325 ]
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. [PubMed:15257633 ]
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. [PubMed:15862515 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonistother/unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 02, 2016 03:12